ClinicalTrials.gg
Not yet recruitingNCT07857837Updated Oct 5, 2026

Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls

A Phase 1 interventional study of Sulthiame in Renal Impairment, sponsored by Shionogi. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Shionogi · Phase 1, Interventional, and Treatment

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 56 under way, 3 of them phase 3. Renal Insufficiency · United States.

Planned enrollment
247th of 468
30 · median 32
Started
2026
with 14 others
Phase 1
232 of 553
14 open now
Primary completion
2026-12
later than 14 of 55 live
Registered
550th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 247th largest by planned enrollment of the 468 interventional ones that give a count, is one of 15 that started in 2026, is one of 232 in phase 1, reaches primary completion later than 14 of the 55 other live ones, and was the 550th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Renal Insufficiency studies recruiting now, 49 (53%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of sulthiame in participants with mild and moderate renal impairment compared to those in healthy participants with normal renal function.

03

Conditions studied

  • Renal Impairment

Browse trials for

Keywords

  • Sulthiame
  • S-054502
  • Renal Impairment
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

All Participants:

  • Participants who are considered to be healthy (for normal renal function participants) or medically stable (for participants with renal impairment), as determined by medical evaluation including previous medical conditions/concurrent medical conditions, physical examination, clinical laboratory tests, vital sign measurements, and 12-lead electrocardiography () during the screening period and on Day -1. Participants with renal impairment should have no changes (based on investigator clinical judgment) in previous medical conditions/concurrent medical conditions or laboratory values within 3 months prior to administration of the intervention on Day 1.
  • Body weight ≥ 60 kilograms (kg) for male and ≥ 50 kg for female and (BMI) within the range 18.5 to 40.0 (inclusive) kg/square meter (m\^2) .

Participants With Renal Impairment (Groups A and B):

  • Participants who have mild and moderate renal impairment based on estimated (eGFR) calculated using the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula and the participant's body surface area (BSA) at the screening visit (Day -28 to -2).

    • Mild renal impairment: 60 to \< 90 milliliters (mL)/minute (min)
    • Moderate renal impairment: 30 to \< 60 mL/min
  • A stable medication regimen is required, defined as not starting new drug(s) or changing dosage(s) within 14 days prior to administration of the investigational intervention through the follow-up/early termination visit.

Healthy Participants With Normal Renal Function (Group C):

  • Participants with clinical laboratory tests within normal reference range for the laboratory, or abnormal but considered not clinically significant by the investigator. Renal function based on eGFR, calculated based on the 2021 CKD EPI creatinine formula and the participant's BSA, must be normal (eGFR ≥ 90 mL/min) at the screening visit.
  • Matched to an individual participant with moderate renal impairment (Group B) with respect to age (± 10 years), body weight (± 10 kg), and sex.

Key Exclusion Criteria:

All Participants:

  • History or presence of/significant history of or current cardiovascular, respiratory, hepatic, gastrointestinal (GI), endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the investigational intervention; or interfering with the interpretation of data.
  • History of GI surgery such as gastrectomy and enterectomy that could lead to clinically significant gastrointestinal dysfunction.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • Participants with fluctuating or rapidly deteriorating renal function.
  • Participation in any other clinical study or any other type of medical research involving administration of an investigational intervention (new chemical entity) within 28 days or 5 half-lives of the investigational intervention (if known) prior to dosing, whichever is longer.

Participants With Renal Impairment (Groups A and B):

  • Participant with clinically significant laboratory values in the opinion of the investigator or outside the protocol-defined ranges or limits during the screening period or on Day -1.

Healthy Participants With Normal Renal Function (Group C):

  • History or presence of/significant history of or current renal disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the investigational intervention; or interfering with the interpretation of data.

Note: Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Group A: Participants with Mild Renal Impairment

    Participants with mild renal impairment will receive a single dose of sulthiame in the fasted state on Day 1.

    Drug: Sulthiame

  • Experimental
    Group B: Participants with Moderate Renal Impairment

    Participants with moderate renal impairment will receive a single dose of sulthiame in the fasted state on Day 1.

    Drug: Sulthiame

  • Experimental
    Group C: Healthy Participants With Normal Renal Function

    Healthy participants with normal renal function will receive a single dose of sulthiame in the fasted state on Day 1.

    Drug: Sulthiame

Interventions

  • Tablet for oral administration

    Also known as: S-054502

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Sulthiame

    Time frame: 0 (predose) up to 168 hours postdose (Day 1 up to Day 8)

  2. Time to Reach Cmax (Tmax) of Sulthiame

    Time frame: 0 (predose) up to 168 hours postdose (Day 1 up to Day 8)

  3. Area Under the Plasma Concentration-time Curve Extrapolated From Time 0 to the time of the Last Quantifiable Concentration After Dosing (AUC0-last) of Sulthiame

    Time frame: 0 (predose) up to 168 hours postdose (Day 1 up to Day 8)

  4. Cmax of Sulthiame Metabolite

    Time frame: 0 (predose) up to 168 hours postdose (Day 1 up to Day 8)

  5. Tmax of Sulthiame Metabolite

    Time frame: 0 (predose) up to 168 hours postdose (Day 1 up to Day 8)

  6. AUC0-last of Sulthiame Metabolite

    Time frame: 0 (predose) up to 168 hours postdose (Day 1 up to Day 8)

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Day 1 up to Day 15

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 2 months later.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 2 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Sep 29, 2026
Primary completionEst.
Dec 4, 2026
CompletionEst.
Dec 11, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857837
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Sep 29, 2026 (estimated)
Primary completion
Dec 4, 2026 (estimated)
Completion
Dec 11, 2026 (estimated)
Last update
Oct 5, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
Contact
Shionogiclintrials-admin@shionogi.co.jp
1-800-849-9707

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sulthiame

Start the discussion